ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0317

Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression

Ivan Ferraz Amaro1, maría García-González2, carmen Ferrer-Moure2, Fuensanta Gómez-Bernal2, Antonia De Vera-González2, Alejandra González Delgado2, Agustín Francisco González-Rivero2, Yolanda Fernández-Cladera2, Juan Carlos Quevedo Abeledo3 and Federico Díaz-González4, 1Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Carotid Artery Disease, complement, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Activation of the classical complement (C) pathway by immune complexes is a characteristic of patients with systemic lupus erythematosus (SLE). Accelerated consumption outstrips synthesis and is the cause of the hypocomplementemia found in the disease. However, a complete characterization of the three pathways (classical -CL-, alternative -AL- and lectin -MBL-) of the C system has not been performed in patients with SLE. In the present work we aim to assess the function of the 3 pathways of C system through both functional assays and the measurement of individual serum components. We then study how full C characterization is related to disease expression.

Methods: New generation functional assays of the three pathways of the C system were performed in 284 patients with SLE (in these ELISA assays the amount of complement activation is expressed in a qualitative way relative to the value of a positive control). Activation of the 3 pathways was defined if its value was below 2 standard deviation of reference values. The concordance of this new generation assays with haemolytic complement (CH50) activity of serum was studied trough the Passing-Bablok method. Additionally, serum levels of C2, C3, C4, C3a, C1q and C1-inhibitor, and factors H and D, were assessed. Patients with SLE were fully characterized including demographics, disease activity (SLEDAI), severity (Katz index) and damage (SLICC) scores, and treatments used in the disease. Multivariable regression analysis was performed to describe the relation of C system to disease patterns and manifestations.

Results: Average CH50 was 44 ± 22 U/ml and it agreed with CL pathway through ELISA. All C pathways were found to be activated compared to reference values: CL (91 ± 38 vs. reference 99 ± 80, p=0.026), AL (47 ± 38 vs 71 ± 21 %, p< 0.001) and MBL (30 ± 42 vs 49 ± 21, p< 0.001). When pathway activation was defined as a binary value according to reference cut-offs, 53% of the patients were found to have no activation of either pathway. Contrary, 18% of the patients had a patter consisting in normal CL, low AL, normal MBL (that ontologically corresponds to a deficiency/activation of properdin or factors B and D); 18% had low CL, low AL, normal MBL; and 6% low CL and normal AL and MBL (deficit of C1q, C1r or C1s). Individual C components analysis confirmed these patterns being lower according to the deficiency/activation of the pattern. SLEDAI and SLICC, but not Katz, were significant associated with lower values of the CL and AL pathways (this was not the case for MBL). Disease activity (SLEDAI >=1) was associated with having a C pattern consisting in low CL and AL and normal MBL (OR 2.52, 95CI 1.28-4.96, p=0.008); this relation was not found with other C deficiency/activation patterns. Besides, although SLICC score correlated with CL and AL pathways, no association was found between this score and any C pattern.

Conclusion: At least, 50% of SLE patients showed activation of the C. All three C pathways showed consumption compared to reference values. The most frequent patterns of activation consist in normal CL, low AL, normal MBL; and low CL and AL, normal MBL. Disease activity, but not damage, was associated with only the pattern of deficiency/activation represented by low CL and AL, and normal MBL.


Disclosures: I. Ferraz Amaro, AbbVie/Abbott, Merck/MSD, Janssen, Roche, AbbVie/Abbott, Pfizer, Roche, Amgen, Celgene, Merck/MSD; m. García-González, None; c. Ferrer-Moure, None; F. Gómez-Bernal, None; A. De Vera-González, None; A. González Delgado, None; A. González-Rivero, None; Y. Fernández-Cladera, None; J. Quevedo Abeledo, None; F. Díaz-González, None.

To cite this abstract in AMA style:

Ferraz Amaro I, García-González m, Ferrer-Moure c, Gómez-Bernal F, De Vera-González A, González Delgado A, González-Rivero A, Fernández-Cladera Y, Quevedo Abeledo J, Díaz-González F. Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/full-characterization-of-the-three-pathways-of-complement-system-in-patients-with-systemic-lupus-erythematosus-relation-to-disease-expression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/full-characterization-of-the-three-pathways-of-complement-system-in-patients-with-systemic-lupus-erythematosus-relation-to-disease-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology